A Phase I/II study of nab-Paclitaxel plus S-1 therapy in previously treated patients with refractory advanced non-small-cell lung cancer - A Phase I/II study of nab-PTX plus S-1 therapy in previously treated patients with refractory advanced NSCLC

Depatment of Thoracic Oncology Osaka Medical Center for Cancer and Cardiovascular Diseases0 个研究点目标入组 45 人开始时间: 2014年1月31日最近更新: 2023年10月17日

试验速览

暂无简介。

•(1)Presencee of other active malignancy (2)SVC syndrome (3)Myocardial infarction, which was developed within six months (4)Liver chirrosis (5)With interstitial pneumonia or pulmonary fibrosis on a chest X-ray (6)Clinically significant drug allergy (7)With severe infection, gastrointestinal hemorrhage or cardiac diseases (8)With persistent diarrhea (9)With with intestinal paralysis or ileus (10)Diabetes with poor control (11)With pericardial effusion, pleural effusion and ascites in need of treatment of drainage (12)Patients received palliative radiotherapy for brain metastases and bone metastases, except for the primary lesion within 2weeks. (13)Symptomatic brain metastasis (14)Peripheral neuropathy of Grade2 or more (15)Positive serum HBs antigen (16)Uncontrolled psychiatric diseases (17)Pregnancy or lactating patients (18)with a history of hypersensitivity to nab-PTX, S-1, paclitaxel, or albumin (19)Others

发起方

Depatment of Thoracic Oncology Osaka Medical Center for Cancer and Cardiovascular Diseases